Nabota's entry into Europe is being delayed
Nabota's entry into Europe is being delayed
  • Kim Min-jee
  • 승인 2019.06.12 11:38
  • 댓글 0
이 기사를 공유합니다

Daewoong Pharmaceutical says, "It doesn't have a direct impact on permission."

 

Daewoong Pharmaceutical's advancement into Europe with its botulinum toxin Nabota (European name: Nuceiva) has been delayed.

According to the bio industry on June 11, the Daewoong Pharmaceutical's U.S.-based partner, Evolus, said in a press release on June 10 that it had been asked by the European Commission to submit supplementary data on Nuceiva and that the final decision on the item's permit could be delayed from the previous schedule. 

Earlier in April, Evolus and Daewoong Pharmaceutical obtained recommendations from the CHMP of the European Medicines Agency (EMA) on the European licensing of Nuceiva on its effects of improving fine wrinkles.

CHMP is an organization that evaluates effectiveness and safety of medicines and presents opinions on licensing to EC. Normally, the CHMP's recommendation for approval of an item's license will be finalized within 90 days of the recommendation. 
However, the final approval decision will be over 90 days as the EC requested supplementary data to review the Nuceiva permit application.

In response, Daewoong Pharmaceutical said, "EC had requested additional documents. Accordingly, the approval schedule may be delayed, but it does not directly affect the approval."


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • Korea IT Times: Copyright(C) 2004, Korea IT Times. .Allrights reserved.
  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • * Mobile News: m.koreaittimes.com
  • * Internet news: www.koreaittimes.com
  • * Editorial Div. 02-578-0434 / 010-2442-9446 * PR Global/AD: 82-2-578-0678.
  • * IT Times Canada: Willow St. Vancouver BC
  • 070-7008-0005
  • * Email: info@koreaittimes.com
ND소프트